Published in Mol Cancer on January 07, 2009
Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One (2010) 1.27
Markers of tumor-initiating cells predict chemoresistance in breast cancer. PLoS One (2010) 1.10
Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. J Exp Clin Cancer Res (2012) 1.10
Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo. PLoS One (2010) 1.10
Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One (2009) 1.08
HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein. PLoS One (2014) 1.07
Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol (2013) 1.05
Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. Sci Transl Med (2014) 1.01
pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol Pharm (2010) 1.00
Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. Cancer Res (2013) 0.99
HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal (2010) 0.90
MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J Biomed Sci (2013) 0.90
Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy. Cell Death Dis (2013) 0.86
Transcriptional regulation of ferritin and antioxidant genes by HIPK2 under genotoxic stress. J Cell Sci (2010) 0.86
Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation. PLoS One (2012) 0.83
Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116. PLoS One (2012) 0.82
Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks. Adv Bioinformatics (2012) 0.79
Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-κB/HIF-1α signal axis. Sci Rep (2016) 0.78
RNA modulators of complex phenotypes in mammalian cells. PLoS One (2009) 0.78
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. Cancer Biol Ther (2016) 0.76
Molecular mechanism of regulation of OGG1: tuberin deficiency results in cytoplasmic redistribution of transcriptional factor NF-YA. J Mol Signal (2009) 0.76
Purine nucleoside analog--sulfinosine modulates diverse mechanisms of cancer progression in multi-drug resistant cancer cell lines. PLoS One (2013) 0.75
Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies. Oncotarget (2017) 0.75
Hyperglycemia triggers HIPK2 protein degradation. Oncotarget (2016) 0.75
Anti-cancer activity of ZnO chips by sustained zinc ion release. Toxicol Rep (2016) 0.75
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A (1993) 6.77
Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol (1996) 5.52
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem (1996) 5.15
Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res (2002) 3.75
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol (2002) 3.24
The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol (2004) 2.74
Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell (2003) 2.42
The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene (2003) 2.22
Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem (1998) 1.90
Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer (2008) 1.62
Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci (2007) 1.48
Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genet Cytogenet (1995) 1.35
What makes tumors multidrug resistant? Cell Cycle (2007) 1.34
HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res (2003) 1.32
Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res (2004) 1.25
Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res (2008) 1.17
Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochim Biophys Acta (2008) 1.11
The P-glycoprotein multidrug transporter. Gen Pharmacol (1996) 1.10
Homeodomain-interacting protein kinase-2 regulates apoptosis in developing sensory and sympathetic neurons. Curr Biol (2004) 1.05
HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations. FEBS Lett (2005) 1.02
Regulation of vascular endothelial growth factor expression by homeodomain-interacting protein kinase-2. J Exp Clin Cancer Res (2008) 0.91
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. Clin Cancer Res (2006) 0.91
Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol (2008) 0.87
HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA. Biochem Biophys Res Commun (2007) 0.84
Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell (2006) 4.10
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell (2005) 2.45
MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell (2007) 2.10
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 1.91
Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle (2011) 1.80
Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ Res (2008) 1.75
Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest (2009) 1.51
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle (2008) 1.36
Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res (2006) 1.33
Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem (2002) 1.29
Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res (2004) 1.25
The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J (2009) 1.23
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J (2009) 1.23
HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. Oncogene (2005) 1.20
Requirement for down-regulation of the CCAAT-binding activity of the NF-Y transcription factor during skeletal muscle differentiation. Mol Biol Cell (2003) 1.19
Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem (2010) 1.18
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther (2009) 1.17
Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res (2008) 1.17
HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res (2009) 1.15
Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest (2002) 1.14
Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck (2007) 1.13
HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. Oncogene (2004) 1.12
Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochim Biophys Acta (2008) 1.11
MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis. J Biol Chem (2003) 1.10
Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo. PLoS One (2010) 1.10
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. PLoS One (2008) 1.08
Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One (2009) 1.08
HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol Cancer (2009) 1.08
Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation. Cancer Res (2010) 1.07
Posttranslational regulation of NF-YA modulates NF-Y transcriptional activity. Mol Biol Cell (2008) 1.06
NF-Y dependent epigenetic modifications discriminate between proliferating and postmitotic tissue. PLoS One (2008) 1.05
The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle (2008) 1.05
Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp Cell Res (2008) 1.05
MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts. Oncogene (2002) 1.04
The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function. Cancer Res (2007) 1.04
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res (2005) 1.03
Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free Radic Biol Med (2010) 1.03
HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations. FEBS Lett (2005) 1.02
Telomerase mediates vascular endothelial growth factor-dependent responsiveness in a rat model of hind limb ischemia. J Biol Chem (2005) 1.01
Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer (2011) 1.00
The inhibition of KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells. PLoS One (2012) 0.98
SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. Oncotarget (2014) 0.97
HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation. Aging (Albany NY) (2011) 0.97
Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Res (2007) 0.96
Purification and characterization of adipose-derived stem cells from patients with lipoaspirate transplant. Cell Transplant (2010) 0.94
Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation. Oncotarget (2011) 0.94
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. Clin Cancer Res (2006) 0.94
Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J Mol Med (Berl) (2008) 0.92
HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition. Cell Cycle (2010) 0.92
Regulation of vascular endothelial growth factor expression by homeodomain-interacting protein kinase-2. J Exp Clin Cancer Res (2008) 0.91
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. Clin Cancer Res (2006) 0.91
deltaEF1 repressor controls selectively p53 family members during differentiation. Oncogene (2005) 0.90
Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link? Aging (Albany NY) (2010) 0.89
Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. Cancer Res (2009) 0.89
A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. J Exp Clin Cancer Res (2013) 0.89
Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res (2006) 0.88
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer (2010) 0.88
Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells. Oncoimmunology (2013) 0.88
Counteracting MDM2-induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells. FEBS Lett (2010) 0.87
Tp53-gene transfer induces hypersensitivity to low doses of X-rays in glioblastoma cells: a strategy to convert a radio-resistant phenotype into a radiosensitive one. Cancer Lett (2006) 0.87
Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol (2008) 0.87
Maternal thyroid hormones are transcriptionally active during embryo-foetal development: results from a novel transgenic mouse model. J Cell Mol Med (2010) 0.87
JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. PLoS One (2013) 0.86
Molecular imaging of nuclear factor-Y transcriptional activity maps proliferation sites in live animals. Mol Biol Cell (2012) 0.86
Axitinib affects cell viability and migration of a primary foetal lung adenocarcinoma culture. Cancer Invest (2014) 0.84
Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis. Cancer (2008) 0.84
HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA. Biochem Biophys Res Commun (2007) 0.84
Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene (2004) 0.83
Homeodomain interacting protein kinase 2: a target for Alzheimer's beta amyloid leading to misfolded p53 and inappropriate cell survival. PLoS One (2010) 0.83
Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation. PLoS One (2012) 0.83
A standardized laboratory and surgical method for in vitro culture isolation and expansion of primary human Tenon's fibroblasts. Cell Tissue Bank (2012) 0.83
Kaposi sarcoma associated herpesvirus (KSHV) induces AKT hyperphosphorylation, bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-1 monocytic cell line. J Exp Clin Cancer Res (2013) 0.83
p53 reactivation: the link to zinc. Cell Cycle (2012) 0.83
Azurin modulates the association of Mdm2 with p53: SPR evidence from interaction of the full-length proteins. J Mol Recognit (2011) 0.82
Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. J Transl Med (2008) 0.81
Interaction of p53 with Mdm2 and azurin as studied by atomic force spectroscopy. J Mol Recognit (2010) 0.81
HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. Cancer Biol Ther (2012) 0.80